Evaluating COVID-19 vaccine effectiveness in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the incidence of recurrent COVID-19 infections, severe pneumonitis, and mortality rates among lung cancer patients receiving systemic antitumor therapies who are vaccinated with a booster dose against those who are not. It is a prospective, open-label, and parallel non-randomized control trial that will also investigate the dynamics of specific antibodies against COVID-19. Blood samples will be collected at various time points to analyze the correlation between antibody levels and breakthrough infections. The study will monitor patient outcomes over a six-month period following vaccination or refusal.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who agree to participate in the trial and sign the informed consents.
2. Male or female, ≥18 years old.
3. Diagnosed of lung carcinoma by histological and cytological examinations.
4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
5. Recorded history of COVID19 infection.
6. Sufficiently functional organs.
7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.

Exclusion Criteria:

1. Life expectance less than 3 months.
2. Less than 3 months since last confirmed COVID-19 infection.
3. Patients unable to return the hospital for follow-up.
4. Patients allergic to COVID-19 vaccine.
5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.

Where it's running

• Peking Union Medical College Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Mengzhao Wang, MD — Peking Union Medical College Hospital
• Study coordinator: Mengzhao Wang, MD
• Email: mengzhaowang@sina.com
• Phone: +8613911235467

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Lattice radiation combined with immunotherapy for advanced solid tumors

  This trial will test whether combining lattice (spatially fractionated) radiation with immunotherapy helps people with advanced or metastatic solid tumors.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07058948

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Induction chemotherapy with low-dose radiation and cadonilimab for locally advanced nasopharyngeal carcinoma

  This study will try adding low-dose radiation and the immune drug cadonilimab to induction chemotherapy before standard concurrent chemoradiotherapy in adults with newly diagnosed locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT05941741

• Combining advanced radiotherapy with immune therapy for lung cancer

  This study is testing a new treatment for advanced lung cancer that combines special radiation therapy with immune therapy to see if it can help patients feel better and improve their outcomes.

  Recruiting Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality and 1 other locations · NCT05754203

• Combining toripalimab with chemotherapy for advanced gastric cancer

  This study is testing if combining a new drug called toripalimab with chemotherapy can help people with advanced stomach cancer do better before surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT04891016

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.